Rezolute Inc (RZLT) - News Archive

An Update on the Therapeutic Horizons: The FDA Eases Restrictions on RZ358 for Congenital Hyperinsulinism Treatment and Enhances Prospects for Clinical Research It is with great elation that we bring forth to the noble...

Additional Funding Boosts Rezolute Inc. s Gross Proceeds to $67M, Impacts Shareholders SignificantlyIn a remarkable turn of events, Rezolute Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to devel...

Rezolute Inc Shares Face Challenges in an Otherwise Positive Year: A Comprehensive AnalysisIn the world of biopharmaceuticals, Rezolute Inc (NASDAQ: RZLT) has been making waves. Recently, investment firm Craig-Hallum an...

Rezolute Inc. Successfully Closes Public Offering, Generating $60M in Gross ProceedsRezolute Inc. has recently announced the successful closing of its underwritten public offering, resulting in approximately $60 million...

Rezolute, Inc. Announces Pricing of Public Offering and Raises $60 Million Rezolute, Inc. (Nasdaq: RZLT), a renowned late-stage biopharmaceutical company dedicated to developing groundbreaking therapies for serious rare...

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants: A Bold Step Towards Transforming Rare Disease TherapiesRezolute, Inc. (Nasdaq: RZLT), a renowned late-stage biopharmaceutical company...

In recent developments, Rezolute, a renowned biopharmaceutical company, has achieved significant milestones in their research of two critical medical conditions - Diabetic Macular Edema (DME) and Congenital Hyperinsulin...

In recent studies, pharmaceutical company Rezolute has made significant progress in the development of two potential treatments for different medical conditions - RZ358 for Non-Islet Cell Tumor Hypoglycemia (NICTH) and...

In a significant milestone for medical research, Rezolute, a prominent biopharmaceutical company, has recently achieved the completion of patient enrollment for its Phase 2 study on Diabetic Macular Edema (DME). This cr...